Faes Farma, S.A. engages in the research, development, manufacture, market, and sale of pharmaceutical products; and raw materials for pharmaceutical use worldwide. The company offers prescription, OTC, and skin-care treatment products. It provides cardiovascular products, such as Drosmina, Hyflon, Venosmil, Venosmil Gel, and Venula; central nervous system products, including Colme, Surmenalit, and Trausan; dermatology products comprising Positón; digestive products, such as Mecolzine; metabolism products, including Dynamogen, Ferroprotina, and Potenciator; Locomotor products comprising Defal, Distem, Dolotren, and Dolotren gel; Bilaxten and Bilidren for allergy; and respiratory products, such as Bronquidiazina CR and Yendol. The company also offers raw materials, including diosmin, hidrosmin, magnesium pidolate, arginine aspartate, granulated diosmin, glutodine, trimethropim, and pyrrolidone carboxylate. In addition, it develops Bilastine, an antihistamine, which is in Phase III clinical trials; F-97013-GD, an atypical antipsychotic that is in pre-clinical phase; F-98214-TA, an antidepressant, which is in pre-clinical phase; and serotonin reuptake inhibitors. Faes Farma, S.A. was founded in 1933 and is headquartered in Bilbao, Spain.
faes farma sa
(FAE:Continuous Market (SIBE))
Avenida Autonomía, 10
Phone: 34 94 481 83 00
Fax: 34 94 481 83 01www.faes.es
|Recordati SpA||€20.48 EUR||+0.17|
|Shire PLC||3,507 GBp||-61.00|
|Procter & Gamble Co/The||$79.90 USD||-1.72|
|View Industry Companies|
Sponsored Financial Commentaries
To contact FAES FARMA SA, please visit www.faes.es. Company data is provided by Capital IQ. Please use this form to report any data issues.